

ONCOLOGY II PANEL

EDITORIAL BOARD LIAISON

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP
Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

PANCREATIC ADENOCARCINOMAS AND ENDOCRINE TUMORS

Authors

Christy S. Harris, Pharm.D., BCPS, BCOP
Assistant Professor
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health
Sciences
Clinical Pharmacy Specialist
Dana-Farber Cancer Institute
Boston, Massachusetts

Audrea H. Szabatura, Pharm.D., BCOP
Oncology Medication Safety Officer
Department of Pharmacy
Dana-Farber Cancer Institute
Boston, Massachusetts

Reviewers

Brian A. Hemstreet, Pharm.D., BCPS
Associate Professor
Director, Pharmaceutical Care Learning Center
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Aurora, Colorado

Paul R. Hutson, Pharm.D., BCOP
Associate Professor
School of Pharmacy
University of Wisconsin
Madison, Wisconsin

Michelle Ganoff, Pharm.D., BCPS
Clinical Specialist, Medicine/ICU
Department of Pharmacy
St. John Hospital and Medical Center
Detroit, Michigan

HEPATIC CANCER

Authors

Sachin R. Shah, Pharm.D., FCCP, BCOP
Associate Professor
Department of Pharmacy Practice
Texas Tech University Health Science Center School
of Pharmacy
Dallas, Texas

Sarah M. Gressett Ussery, Pharm.D., BCOP
Hematology/Oncology Clinical Pharmacy Specialist
Department of Pharmacy
VA North Texas Healthcare System
Dallas, Texas

Reviewers

Lisa C. Hutchison, Pharm.D., MPH, FCCP, BCPS
Associate Professor
Pharmacy Practice
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Bernard Lee, Pharm.D., BCPS
Pharmacy Practice Residency Program Director
Department of Pharmacy Services
Mayo Eugenio Litta Children's Hospital at Mayo
Clinic
Rochester, Minnesota

Jolynn Knoche Sessions, Pharm.D., BCOP
Oncology Clinical Pharmacist Specialist
Director, ESA Anemia Clinic
Department of Pharmacy
Charles George VA Medical Center
Asheville, North Carolina

HEAD AND NECK CANCER

Author

Sarah L. Scarpace, Pharm.D., BCOP
Assistant Dean for Pharmacy Professional Affairs
Associate Professor, Pharmacy Practice
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Clinical Oncology Pharmacist
Department of Pharmacy
Stratton VA Medical Center
Albany, New York

Reviewers

Janet M. Bramell, Pharm.D., BCPS, BCOP
Clinical Pharmacy Specialist, Oncology
Department of Pharmacy
VA Tennessee Valley Healthcare System
Nashville, Tennessee
Assistant Professor
Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Memphis, Tennessee

Emilie L. Karpiuk, Pharm.D., BCPS, BCOP
Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 6, Oncology II chapters:

H. Gwen Bartlett, Pharm.D., BCPS
Clinical Pharmacist III
Department of Pharmacy
St. Francis Health Center
Topeka, Kansas

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
Park Nicollet Health Services Methodist Hospital
Minneapolis, Minnesota

Mary Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: David Baribeault (Amgen, Watson, Eisai); Shannon W. Finks (Novartis Pharmaceuticals); Myke Green (Merck, Sanofi-Aventis); Brian A. Hemstreet (Conexus Health); Viet Ho (Cephalon Oncology); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Paul Hutson (Projections Research, Inc., Mithridion); Patrick Kiel (Genzyme, Sanofi-Aventis); Michelle Richardson (Amgen, QualityMetric); Sarah Scarpace (Pfizer, TopoTarget, Millennium Pharmaceuticals, Merck); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jamie Shapiro (Genzyme); Jeffrey T. Sherer (Sturges-Weber Foundation); Judith Smith (AdvoCare);

Stock Ownership: Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health);

Royalties: William Figg (Kaplan, Springer); Lisa C. Hutchison (ASHP); Helen Leather (Genzyme, Novartis, Bayer, Amgen, Pfizer)

Grants: William Figg (NIH, Tracon); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants],

HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Michelle Richardson (NIH NIDDK [two grants]); Judith Smith (Merck, SignPath Pharma, Amino UP Chemical)

Honoraria: David Baribeault (Amgen, Eisai, Roche); Christopher Fausel (Amgen, Millennium Pharmaceuticals); Lisa C. Hutchison (ACCP, ASHP); Patrick Kiel (Genzyme); Helen LoSasso (New Jersey Society of Health-System Pharmacists, New Jersey Pharmacists Association); April Miller (Boehringer-Ingelheim, ZymoGenetics); Michelle Richardson (Amgen); Jamie Shapiro (Genzyme)

Other:

Nothing to Disclose: Ola Adejuwon, Laura Bobolts, Janet Bramell, Julianna Merten, Clarence Chant, Margaret Charpentier, Michelle Ganoff, Christy Harris, Kellie Jones, Shaun Keegan, Bernard Lee, Dayna McCauley, Marianne McCollum, April Miller, Jolynn Sessions, Sachin Shah, Audrea Szabatura, Sarah Ussery

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org